Astellas/Cardiome Anticipate Oct. 19 Vernakalant User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas’ resubmission of the atrial fibrillation agent’s NDA triggers a $10 million milestone payment to Cardiome.
You may also be interested in...
Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible
Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.
Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible
Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.
FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs
Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.